ANI Pharmaceuticals, Inc. has announced the launch of Erythromycin Ethylsuccinate for Oral Suspension 200mg/5mL indicated as a treatment for various infections. The current annual U.S. market for this product is approximately $78 million, according to IMS Health, and is representative of two brand products. ANI will immediately launch the product.
Arthur S. Przybyl, ANI's President and CEO stated, "This is the first product that we are launching from the basket of 22 previously marketed generic products that we acquired in July 2015 and it represents another successful manufacturing site transfer and re-commercialization of a previously discontinued ANDA product. ANI has added nine new products to our commercial portfolio in 2017 and we continue to forecast the launch of at least one additional generic product this year."